Article

Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial

2022-08-08

Abstract excerpt

<h4>Background</h4> The development of vaccines to control the COVID-19 pandemic progression is a worldwide priority. CoronaVac ® is an inactivated SARS-CoV-2 vaccine approved for emergency use with robust efficacy and immunogenicity data reported in trials in China, Brazil, Indonesia, Turkey, and Chile. <h4>Methods</h4> This study is a randomized, multicenter, and controlled phase 3 trial in healthy Chilean a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 77abf63f-4bfa-5404-8bf7-6a4f93b06fd2
DOI: 10.1101/2022.08.05.22278464

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trialDOI 10.1101/2022.08.05.22278464Read

Safety and efficacy of two immunization schedules with an inactivated SARS-CoV-2 vaccine in adults. A randomized non-inferiority clinical trialSemantic proximity Read

Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using two-dose primary protocol in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow upSemantic proximity Read

An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccineSemantic proximity Read

A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concernSemantic proximity Read

An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in ChileSemantic proximity Read

Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 StudySemantic proximity Read

Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccinationSemantic proximity Read

Cohort Profile: The Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 vaccines (ENFORCE)Semantic proximity Read

Phase I Trial of a Multi-Peptide COVID-19 Vaccine for the Induction of SARS-CoV-2 T-Cell ImmunitySemantic proximity Read

Real-world monitoring of BNT162b2 vaccine-induced SARS-CoV-2 B and T cell immunity in naive healthcare workers: a prospective single center studySemantic proximity Read

The Third Dose of the SARS-CoV-2 Vaccine: Why and for Whom?Semantic proximity Read

Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 S antibodiesSemantic proximity Read